Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Healthline5d
Mounjaro Injection Overview
Mounjaro contains the active ingredient tirzepatide. (An active ingredient is what makes a drug work.) Another drug, Zepbound, also contains the same active ingredient and is approved for weight loss.
Healthline7d
GLP-1 Drugs Benefit Brain and Heart Health, but May Cause Kidney, GI Issues
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
The Motley Fool3d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While weight loss is an enormous opportunity, Lilly has a broad portfolio of medications treating many different pockets of the healthcare landscape. Beyond Mounjaro and Zepbound, I'd encourage ...